STTK News and Press, Shattuck Labs Inc.

2024-06-14 19:15:01 ET BTIG analyst issues NEUTRAL recommendation for STTK on June 14, 2024 05:34PM ET. STTK was trading at $6.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...

2024-06-14 07:07:40 ET More on Shattuck Labs Seeking Alpha’s Quant Rating on Shattuck Labs Historical earnings data for Shattuck Labs Financial information for Shattuck Labs Read the full article on Seeking Alpha For further details see: Sh...

– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% ORR in frontli...

2024-06-10 10:07:22 ET More on Shattuck Labs Seeking Alpha’s Quant Rating on Shattuck Labs Historical earnings data for Shattuck Labs Financial information for Shattuck Labs Read the full article on Seeking Alpha For further details see: Sh...

AUSTIN, TX and DURHAM, NC, June 10, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmun...

- Conference call and webcast to be held June 14, 2024 at 7:30 a.m. ET featuring lead investigator - AUSTIN, TX and DURHAM, NC, June 06, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional ...

– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML patients to hematopoietic cell transplantation – – SL-172154 continued t...

2024-05-02 08:05:19 ET More on Shattuck Labs Two biotech/pharma stocks to watch - STTK, KALV Seeking Alpha’s Quant Rating on Shattuck Labs Historical earnings data for Shattuck Labs Financial information for Shattuck Labs Read the full articl...

- Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 Annual Meeting in June – - Randomized,...

2024-04-16 19:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...